Abstract: Combinations of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor are described for treatment of inflammation and inflammation-related disorders.

Abstract: A class of substituted oxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II ##STR1## wherein R is selected from halo, mercapto, hydroxyl, lower carboxyalkylthio, lower haloalkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkoxy, aryloxy, lower alkylamino, aminocarbonyl, lower alkoxyalkyl, and lower carboxy(haloalkyl); wherein R.sup.2 is selected from lower alkyl and amino; and wherein R.sup.4 is selected from hydrido, lower alkyl, lower alkylamino, lower alkoxy and halo; or a pharmaceutically-acceptable salt thereof.

Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I: ##STR1## wherein R.sup.1, R.sup.2, Ar.sup.1 and HetAr.sup.2 are as described in the specification.

Abstract: A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I'wherein X, A.sup.1, A.sup.2, A.sup.3, A.sup.4, R, R", R.sup.1 and R.sup.2 are as described in the specification.

Abstract: The invention relates to a method of detecting concentrations of cyclooxygenase-2 in a mammal, the method comprising: administering to the mammal a diagnostically effective amount of a cyclooxygenase-2 selective agent, which is capable of being detected in vivo; and b) detecting the agent so the concentration of cyclooxygenase-2 is detected.

Abstract: A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I' ##STR1## wherein X, A.sup.1, A.sup.2, A.sup.3, A.sup.4, R, R", R.sup.1 and R.sup.2 are as described in the specification.

Abstract: A class of pyrazolyl compounds is described for use in treating inflammation and inflammation related disorders. Compounds of particular interest are defined by Formula I: ##STR1## wherein R.sup.1 is selected from hydrido, C.sub.1 -C.sub.20 -alkyl, C.sub.2 -C.sub.20 -alkenyl, C.sub.2 -C.sub.20 -alkynyl, C.sub.1 -C.sub.20 -haloalkyl, aryl-C.sub.1 -C.sub.20 -alkyl, heterocyclic-C.sub.1 -C.sub.20 -alkyl, heteroaryl-C.sub.1 -C.sub.20 -alkyl, C.sub.1 -C.sub.20 -hydroxyalkyl, C.sub.1 -C.sub.10 -alkoxyalkyl, C.sub.1 -C.sub.20 -cyanoalkyl, C.sub.1 -C.sub.20 -aminoalkyl, C.sub.1 -C.sub.20 -alkylamino-C.sub.1 -C.sub.20 -alkyl, carboxy-C.sub.1 -C.sub.20 -alkyl, C.sub.1 -C.sub.20 -alkoxycarbonyl-C.sub.1 -C.sub.20 -alkyl, C.sub.1 -C.sub.20 -alkylaminocarbonyl-C.sub.1 -C.sub.20 -alkyl, N-hydroxyaminocarbonyl-C.sub.1 -C.sub.20 -alkyl, N-hydroxy-N-C.sub.1 -C.sub.20 -alkyl-aminocarbonyl-C.sub.1 -C.sub.20 -alkyl, arylaminocarbonyl-C.sub.1 -C.sub.20 -alkyl and aminocarbonyl-C.sub.1 -C.sub.20 -alkyl;wherein R.sup.

Abstract: This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating angiogenic disorders.

Abstract: A class of compounds for the treatment of viral infections. Compounds of particular interest are defined by Formula II ##STR1## wherein R.sup.28 is selected from (a) amino substituted with one or two radicals selected from alkyl, aralkyl, heterocycoalkyl, heterocyclo, and aryl, and (b) amino acid residues and derivatives thereof; wherein R.sup.29 is selected from hydrido, alkyl, halo, ##STR2## wherein R.sup.30 is selected from alkyl, alkoxy, alkylamino, carboxyalkyl, alkoxyalkyl, alkylaminoalkyl, cycloalkyl, heterocyclo, heterocycloalkyl, heterocycloalkoxy, alkylaminoalkoxy, alkylaminoalkylamino, heterocycloalkylamino, and N-aralkylamino; wherein R.sup.31 is alkyl; wherein R.sup.32 is alkyl and aryl; or a pharmaceutically-acceptable salt thereof.

Abstract: A class of substituted isoxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II ##STR1## wherein R.sup.1 is selected from hydroxyl, lower alkyl, carboxyl, lower carboxyalkyl, lower aminocarbonylalkyl, lower alkoxycarbonylalkyl, lower aralkyl, lower alkoxyalkyl, lower aralkoxyalkyl, lower alkylthioalkyl, lower aralkylthioalkyl, lower alkylaminoalkyl, lower aryloxyalkyl, lower arylthioalkyl, lower haloalkyl, lower hydroxylalkyl, cycloalkyl, cycloalkylalkyl, and aralkyl; wherein R.sup.3 is selected from cycloalkyl, cycloalkenyl, aryl, and heteroaryl; wherein R.sup.

Abstract: A vaccine is described which comprises an assembly-deficient herpesvirus. The mutant herpesvirus is capable of infecting and undergoing DNA replication in the cells of a susceptible mammal, but is defective in capsid assembly and formation of mature virion particles. The assembly-deficient herpesvirus is avirulent and capable of generating a protective immune response in a vaccinated mammal.

Abstract: This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. In particular, the invention describes the method of preventing and treating epithelial cell neoplasia in a subject, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula I. ##STR1## wherein A, R.sup.2 and R.sup.3 are as described in the specification.

Abstract: A class of compounds which are (H.sup.+ /K.sup.+)ATPase inhibitors can be used for the treatment of viral infections. Compounds of particular interest are defined by Formula III: ##STR1## wherein D is N or CH; wherein R.sup.7 is one or more radicals selected from hydrido, alkoxy, amino, cyano, nitro, hydroxyl, alkyl, halo, haloalkyl, carboxyl, alkanoyl, nitro, amino, alkylamino, aminocarbonyl, aminosulfonyl, alkylaminocarbonyl, alkylcarbonylamino, alkoxycarbonyl, alkylaminosulfonyl, alkylsulfonylamino, alkylthio, alkylsulfinyl and alkylsulfonyl; wherein R.sup.8 is selected from hydrido, alkyl and cycloalkyl; wherein R.sup.9 is one or more radicals selected from hydrido, alkoxy, amino, alkyl, halo, cyano, nitro, hydroxyl, haloalkyl, nitro, carboxyl, alkanoyl, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, alkylcarbonylamino, aminosulfonyl, alkylaminosulfonyl, alkylsulfonylamino, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; and wherein R.sup.10 and R.sup.

Abstract: A class of pyrrolyl derivatives is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described in the specification.

Abstract: Prodrugs of COX-2 inhibitors are described as being useful in treating inflammation and inflammation-related disorders.

Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders.

Abstract: A class of substituted pyridyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II wherein R.sup.1 is selected from hydrido, halo, alkoxy, haloalkoxy, aryl, alkylthio, alkylamino, aralkoxy, azido and alkenyloxy; wherein R.sup.2 is selected from hydrido, cyano, hydroxyalkyl, haloalkyl, aminoalkyl, alkylaminoalkyl, alkylcarbonyloxyalkyl, aminocarbonyl and alkylcarbonylaminoalkyl; and wherein R.sup.5 and R.sup.6 are one or more radicals independently selected from halo, alkylsulfonyl, aminosulfonyl, alkoxy and alkylthio; provided one of R.sup.5 and R.sup.6 is substituted with alkylsulfonyl, aminosulfonyl, or haloalkylsulfonyl; or a pharmaceutically-acceptable salt thereof.

Abstract: An efficient synthesis of 3-haloalkyl-1H-pyrazoles, suitable for adoption in a safe, large-scale process, has been developed.

Abstract: A class of 1,3,5-substituted pyrazoles is described for the treatment of inflammation, including treatment of pain and disorders such as arthritis. Compounds of particular interest are of Formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as described herein; or a pharmaceutically-acceptable salt thereof.

Abstract: An efficient synthesis of 3-haloalkyl-1H-pyrazoles, suitable for adoption in a safe, large-scale process, has been developed.